| Year |
Citation |
Score |
| 2019 |
Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, ... ... Binder GK, et al. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. Journal For Immunotherapy of Cancer. 7: 276. PMID 31651363 DOI: 10.1186/S40425-019-0762-2 |
0.43 |
|
| 2019 |
Stadtmauer EA, Faitg TH, Lowther DE, Badros AZ, Chagin K, Dengel K, Iyengar M, Melchiori L, Navenot JM, Norry E, Trivedi T, Wang R, Binder GK, Amado R, Rapoport AP. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Advances. 3: 2022-2034. PMID 31289029 DOI: 10.1182/Bloodadvances.2019000194 |
0.413 |
|
| 2018 |
D'Angelo SP, Melchiori L, Merchant MS, Bernstein DB, Glod J, Kaplan RN, Grupp SA, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, et al. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259T cells in Synovial Sarcoma. Cancer Discovery. PMID 29891538 DOI: 10.1158/2159-8290.Cd-17-1417 |
0.387 |
|
| 2018 |
Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G. Fludarabine and neurotoxicity in engineered T-cell therapy. Gene Therapy. PMID 29789639 DOI: 10.1038/S41434-018-0019-6 |
0.424 |
|
| 2009 |
Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1453-64. PMID 19384291 DOI: 10.1038/Mt.2009.83 |
0.446 |
|
| 2009 |
Wang GP, Levine BL, Binder GK, Berry CC, Malani N, McGarrity G, Tebas P, June CH, Bushman FD. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 844-50. PMID 19259065 DOI: 10.1038/Mt.2009.16 |
0.482 |
|
| 2006 |
Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B, June CH. Gene transfer in humans using a conditionally replicating lentiviral vector. Proceedings of the National Academy of Sciences of the United States of America. 103: 17372-7. PMID 17090675 DOI: 10.1073/Pnas.0608138103 |
0.508 |
|
| 2005 |
Braun SE, Wong FE, Connole M, Qiu G, Lee L, Gillis J, Lu X, Humeau L, Slepushkin V, Binder GK, Dropulic B, Johnson RP. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 1157-67. PMID 16168713 DOI: 10.1016/J.Ymthe.2005.07.698 |
0.557 |
|
| 2005 |
Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, Schonely K, Ni Y, Binder GK, Levine BL, MacGregor RR, June CH, Dropulic B. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Human Gene Therapy. 16: 17-25. PMID 15703485 DOI: 10.1089/Hum.2005.16.17 |
0.365 |
|
| 2005 |
Ni Y, Sun S, Oparaocha I, Humeau L, Davis B, Cohen R, Binder G, Chang Y, Slepushkin V, Dropulic B. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. Journal of Gene Medicine. 7: 818-834. PMID 15693055 DOI: 10.1002/Jgm.726 |
0.47 |
|
| 2005 |
Dropulic B, MacGregor R, Rebello T, Manilla P, Humeau L, Lu X, Slepushkin V, Binder GK, Ybarra C, Levine BL, Bushman F, June CH. 1075. Phase I Clinical Trial Demonstrates Safety and Feasibility of Autologous Cellular Therapy with Lentiviral Modified CD4 T Cells Expressing Anti-HIV Antisense in Patients with HAART Resistant HIV-1 Infection Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.622 |
0.519 |
|
| 2005 |
MacGregor RR, Levine BL, Lu X, Humeau LM, Rebello T, Manilla P, Ni Y, Binder GK, Carroll R, Boyer J, Bushman F, Slepushkin V, Dropulic B, June CH. 990. Unexpected Immune Enhancement by Autologous Lentiviral Modified CD4 T Cells: Results from a Phase I Gene Transfer Trial of Lentiviral Vector-Modified T Cells Expressing Antisense Envelope Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.537 |
0.56 |
|
| 2005 |
Chen C, Lu J, Slepushkina T, Worden A, Slepushkin V, Humeau LM, Binder GK, Lu X. 477. Development of SIV Based Vectors with Efficient Delivery for Vector Dynamic Studies in the Simian System Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.017 |
0.528 |
|
| 2005 |
Braun SE, Eng F, Connole M, Chen C, Dropulic B, Binder GK, Lu X, Johnson RP. 62. Transduction of CD34+ Hematopoietic Progenitor Cells with a SIV-Based Lentiviral Vector Expressing Antisense SIV Env Protects CD4+ T Cell Progeny from SIVmac239 Infection Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.090 |
0.543 |
|
| 2004 |
Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T, Chen Z, Merling R, Davis B, Chang YN, Dropulic B. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. The Journal of Gene Medicine. 6: 963-73. PMID 15352069 DOI: 10.1002/Jgm.593 |
0.481 |
|
| 2004 |
Lu X, Yu Q, Binder GK, Chen Z, Slepushkina T, Rossi J, Dropulic B. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. Journal of Virology. 78: 7079-88. PMID 15194784 DOI: 10.1128/Jvi.78.13.7079-7088.2004 |
0.469 |
|
| 2004 |
Humeau LM, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, Pereira M, Slepushkina T, Barnett S, Dropulic LK, Carroll R, Levine BL, June CH, Dropulic B. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Molecular Therapy : the Journal of the American Society of Gene Therapy. 9: 902-13. PMID 15194057 DOI: 10.1016/J.Ymthe.2004.03.005 |
0.525 |
|
| 2004 |
Davis BM, Humeau L, Slepushkin V, Binder G, Korshalla L, Ni Y, Ogunjimi EO, Chang LF, Lu X, Dropulic B. ABC transporter inhibitors that are substrates enhance lentiviral vector transduction into primitive hematopoietic progenitor cells. Blood. 104: 364-73. PMID 15059841 DOI: 10.1182/Blood-2003-07-2363 |
0.396 |
|
| 2004 |
Dropulic B, Humeau L, Binder GK, Lu X, Slepushkin V, Merling R, Echeagaray P, Pereira M, Slepushkina T, Barnett S, Dropulic LK, Carroll R, Levine B, MacGregor RR, June CH. 1003. HIV-1-Derived Lentivirus Vector-Based Antisense Gene Therapy: Towards an Alternative Treatment for HIV/AIDS Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.941 |
0.542 |
|
| 2004 |
Lu X, Chen Z, Molina R, Ramamurthy P, Binder GK, Dropulic B. 6. Investigations into the Relative Safety of Lentiviral Vectors to Oncoretroviral Vectors Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.05.085 |
0.517 |
|
| 2003 |
Binder GK, Griffin DE. Immune-mediated clearance of virus from the central nervous system. Microbes and Infection / Institut Pasteur. 5: 439-48. PMID 12738000 DOI: 10.1016/S1286-4579(03)00047-9 |
0.504 |
|
| 2003 |
Dropulic B, Schonely K, Slepushkin V, Lu X, Andre K, Boehmer J, Bengston K, Doub M, Cohen R, Berlinger D, Slepushkina T, Chen Z, Li Y, Binder G, Davis B, et al. QC Release Testing of an HIV-1 Based Lentiviral Vector Lot and Transduced Cellular Product Bioprocessing Journal. 2: 39-47. DOI: 10.12665/J24.Dropulic |
0.378 |
|
| 2001 |
Binder GK, Griffin DE. Interferon-gamma-mediated site-specific clearance of alphavirus from CNS neurons. Science (New York, N.Y.). 293: 303-6. PMID 11452126 DOI: 10.1126/Science.1059742 |
0.523 |
|
| Show low-probability matches. |